Skip to search formSkip to main contentSkip to account menu

Gilenya

Known as: Gilenia 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

fingolimodfingolimod hydrochloride
fingolimod 0.5 MG Oral Capsule [Gilenya]fingolimod Oral Capsule [Gilenya]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
[The results of a randomized open multicenter comparative study on the tolerability and safety of gilenya (fingolimod) in patients with remitting multiple sclerosis].
At the present time, disease modifying drugs (DMD) for treatment of patients with multiple sclerosis are used to reduce the risk… 
2013
2013
[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
: We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG… 
2013
2013
[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG… 
Review
2011
Review
2011
ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
M ultiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) that is the leading cause of… 
2011
2011
Update in neurology.
One important step in modern treatment of multiple sclerosis is recent FDA approval for oral imunomodulatory therapy in the last… 
2010
2010
FTY720 and central memory
The oral sphingosine 1 phosphate modulator, FTY-720 (Fingolimod, Gilenia®), demonstrated efficacy in 2 relapsing-remitting… 
Review
2010
Review
2010
Orphan drug workshops
389 suppressive effects, it could find a niche as part of a combination therapy. “Daclizumab has been used with lots of other… 
Review
2010
Review
2010
Ariad's NF-κB blow
389 suppressive effects, it could find a niche as part of a combination therapy. “Daclizumab has been used with lots of other… 
Review
2010
Review
2010
Market watch: Key clinical and regulatory events in Q2 2010
Promising news on several therapies for severe and unmet medical needs is anticipated in the second quarter of 2010. A US FDA… 
Review
2010
Review
2010
Novartis eyes oral MS drug as potential blockbuster
1135 has shown side effects that include a slowed heart rate, macular edema and breathing and liver problems. Although these may… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)